DE60034694T2 - Verwendung von elastase zur öffnung verstopfter arterien und venen - Google Patents

Verwendung von elastase zur öffnung verstopfter arterien und venen Download PDF

Info

Publication number
DE60034694T2
DE60034694T2 DE2000634694 DE60034694T DE60034694T2 DE 60034694 T2 DE60034694 T2 DE 60034694T2 DE 2000634694 DE2000634694 DE 2000634694 DE 60034694 T DE60034694 T DE 60034694T DE 60034694 T2 DE60034694 T2 DE 60034694T2
Authority
DE
Germany
Prior art keywords
vein
artery
use according
drug
elastase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2000634694
Other languages
German (de)
English (en)
Other versions
DE60034694D1 (de
Inventor
Nicholas F. Laurel FRANANO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protara Therapeutics Inc
Original Assignee
Proteon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics Inc filed Critical Proteon Therapeutics Inc
Application granted granted Critical
Publication of DE60034694D1 publication Critical patent/DE60034694D1/de
Publication of DE60034694T2 publication Critical patent/DE60034694T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Processing Of Meat And Fish (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2000634694 1999-09-24 2000-09-24 Verwendung von elastase zur öffnung verstopfter arterien und venen Expired - Lifetime DE60034694T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24
US155938P 1999-09-24
PCT/US2000/026237 WO2001021574A1 (en) 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits

Publications (2)

Publication Number Publication Date
DE60034694D1 DE60034694D1 (de) 2007-06-14
DE60034694T2 true DE60034694T2 (de) 2008-01-17

Family

ID=22557384

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2000634694 Expired - Lifetime DE60034694T2 (de) 1999-09-24 2000-09-24 Verwendung von elastase zur öffnung verstopfter arterien und venen

Country Status (11)

Country Link
EP (4) EP1923068B1 (cg-RX-API-DMAC7.html)
JP (2) JP5763286B2 (cg-RX-API-DMAC7.html)
AT (2) ATE511854T1 (cg-RX-API-DMAC7.html)
AU (1) AU7612100A (cg-RX-API-DMAC7.html)
CA (1) CA2385488C (cg-RX-API-DMAC7.html)
CY (3) CY1106656T1 (cg-RX-API-DMAC7.html)
DE (1) DE60034694T2 (cg-RX-API-DMAC7.html)
DK (3) DK1220830T3 (cg-RX-API-DMAC7.html)
ES (3) ES2364191T3 (cg-RX-API-DMAC7.html)
PT (3) PT1220830E (cg-RX-API-DMAC7.html)
WO (1) WO2001021574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
CA2517006A1 (en) * 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
JP2008513517A (ja) * 2004-09-22 2008-05-01 プロテオン セラペウチクス インコーポレーテッド 生物学的導管の疾患の治療方法及び予防方法
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
HUE046160T2 (hu) 2012-01-12 2020-02-28 Endo Global Ventures Clostridium histolyticum enzim
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
ES3036011T3 (en) 2017-03-01 2025-09-11 Endo Operations Ltd Apparatus and method for assessing and treating cellulite
CN118325876A (zh) 2017-03-28 2024-07-12 恩多风投有限公司 生产胶原酶的改进方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
JP3054190B2 (ja) * 1989-01-27 2000-06-19 イムノリティックス・インコーポレイテッド 良性前立腺肥大処置のための組成物および方法
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
EP0815202B1 (en) * 1994-12-13 2007-02-21 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
EP1220830B1 (en) 2007-05-02
PT1923068E (pt) 2011-07-29
ATE511854T1 (de) 2011-06-15
JP2003523319A (ja) 2003-08-05
CY1117932T1 (el) 2017-05-17
DE60034694D1 (de) 2007-06-14
CY1112329T1 (el) 2015-12-09
CA2385488C (en) 2015-07-07
EP2332568A1 (en) 2011-06-15
EP2363142B1 (en) 2015-03-25
HK1162302A1 (en) 2012-08-31
PT1220830E (pt) 2007-06-11
ES2284528T3 (es) 2007-11-16
ES2534938T3 (es) 2015-04-30
WO2001021574A1 (en) 2001-03-29
ES2364191T3 (es) 2011-08-26
EP2363142B8 (en) 2015-06-10
EP2363142A1 (en) 2011-09-07
PT2363142E (pt) 2015-08-04
EP1220830A4 (en) 2005-03-30
DK1923068T3 (da) 2011-06-27
ATE361095T1 (de) 2007-05-15
EP1923068B1 (en) 2011-06-08
JP5793461B2 (ja) 2015-10-14
EP1220830A1 (en) 2002-07-10
JP5763286B2 (ja) 2015-08-12
JP2012131830A (ja) 2012-07-12
CA2385488A1 (en) 2001-03-29
DK2363142T3 (en) 2015-04-20
DK1220830T3 (da) 2007-07-16
EP1923068A1 (en) 2008-05-21
CY1106656T1 (el) 2012-01-25
EP2363142A9 (en) 2011-10-19
WO2001021574A9 (en) 2002-12-27
AU7612100A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
US8562983B2 (en) System comprising elastase
JP5793461B2 (ja) 閉塞した生物学的管を開通するためのシステムと方法
JP2011001379A (ja) 生体導管の疾患を治療および予防するための方法
US10179163B2 (en) Methods of treatment with elastase
DE10024752A1 (de) Mittel und Vorrichtung zur Behandlung von Prostata-Erkrankungen
DE69528573T2 (de) Verwendung einer Zubereitung enthaltend einen Plasminogen-Aktivator für die Verbesserung der Wundheilung
DE602005003836T2 (de) Verwendung von botulinumtoxin zur herstellung eines medikaments zur behandlung der lithiasis der speicheldrüse, der gallenblase, der niere oder des pankreas
HK1162302B (en) Elastase for opening obstructed biological conduits
RU2222269C2 (ru) Способ лечения панкреонекроза
DE69525728T2 (de) Verminderung des Fettgewebes durch Verwendung von Kollagenase
US20090196865A1 (en) Methods for the treatment and prevention of diseases of biological conduits
Hillmer et al. Limitations of studying keloid scars using the nude athymic mouse model

Legal Events

Date Code Title Description
8364 No opposition during term of opposition